Privi Speciality Chemicals Q2 FY27: Record Sales & Profit, Declares First Interim Dividend
Privi Speciality Chemicals reported record Q2 FY27 sales of ₹773 crore and EBITDA of ₹212 crore, with PAT up 25% YoY. The company declared its first interim dividend of ₹5 per share. Phase 1 capacity expansion is complete, and the company reiterated its 20% annual growth guidance, targeting ₹5,000 crore revenue by 2030.
Record financial performance, declaration of a first-ever dividend, and a clear growth strategy with significant capex plans are material events that are likely to have a high impact on investor sentiment and the company's valuation.
The company reported record sales and profitability, declared its first-ever interim dividend, and reiterated a strong growth outlook, indicating positive financial health and future prospects.
Privi Speciality Chemicals Limited announced its strongest ever quarterly performance for the quarter and half year ended September 30, 2026. The company achieved record sales of ₹773 crores and EBITDA of ₹212 crores. Profit after tax (PAT) for the quarter stood at ₹117 crores, a growth of approximately 25% year-on-year. For the first half of FY27, PAT was ₹201 crores, up by about 29% compared to the previous year.
Reflecting confidence in its business and commitment to shareholder value, the Board declared the company's first-ever interim dividend of ₹5 per share. The company reported total income of ₹773.16 crores for Q2 FY27, a 13.9% increase year-on-year, with EBITDA at ₹212.49 crores, up 16.66%. PAT grew by 24.61% to ₹117.03 crores.
Operational priorities focused on preparing for the next stage of growth, including capacity expansion. Phase 1 of the expansion program, designed to increase capacity from 48,000 to 54,000 metric tons per annum, was completed as of September 30, 2026. The company is on course to implement new molecules as part of subsequent expansion phases. The joint venture, PRIGIV, achieved its first profitable quarter in Q4 FY26 and continued its profitability in Q2 FY27.
The company reiterated its 20% growth guidance for the financial year and expects to maintain this momentum. Future plans include significant investments in Phase 2 and Phase 3 capex, targeting substantial revenue contributions from new specialty chemicals and expansion projects by 2030, aiming for a revenue of ₹5,000 crores. The balance sheet remains strong with a ROCE of 24.30% and ROE of 26.34%, and a net debt-to-EBITDA ratio of 1.07x.
What to do with a filing like this
Privi Speciality Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Privi Speciality Chemicals Limited. Read the original for the full detail.